Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Rhea-AI Summary

Keros Therapeutics, Inc. (Nasdaq: KROS) announced participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 3:40 PM ET. CEO Jasbir S. Seehra, Ph.D., and CFO Keith Regnante will discuss the company's innovative treatments aimed at hematological, pulmonary, and musculoskeletal disorders. A live audio webcast will be available, and an archived replay can be accessed for 90 days on Keros' website. Keros focuses on developing therapies like KER-050, KER-047, and KER-012 for various medical needs.

LEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary, and musculoskeletal disorders with high unmet medical need, today announced that Jasbir S. Seehra, Ph.D, President and Chief Executive Officer, and Keith Regnante, Chief Financial Officer, will participate in a fireside chat presentation at the Morgan Stanley 20^th Annual Global Healthcare Conference on Monday, September 12, 2022 at 3:40 pm Eastern time.

A live audio webcast of the fireside chat presentation will be available at https://event.webcasts.com/starthere.jsp?ei=1566890&tp_key=ccabae4d4a&tp_special=8 and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance. Keros’ third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta.

Investor Contact:
Deepankar Roy
droy@kerostx.com
213-268-1878

FAQ

What is the date and time of Keros Therapeutics' presentation at the Morgan Stanley Global Healthcare Conference?

Keros Therapeutics will present on September 12, 2022, at 3:40 PM Eastern Time.

Who from Keros Therapeutics will participate in the fireside chat?

CEO Jasbir S. Seehra, Ph.D., and CFO Keith Regnante will participate.

How can I access the live audio webcast of Keros Therapeutics' presentation?

The live audio webcast can be accessed through Keros Therapeutics' official website.

What are the main product candidates under development by Keros Therapeutics?

Keros is developing KER-050 for cytopenias, KER-047 for anemia from iron imbalance, and KER-012 for pulmonary arterial hypertension.

Where can I find the archived replay of Keros Therapeutics' presentation?

An archived replay will be available on the Investors section of the Keros Therapeutics website for up to 90 days after the event.